[
    [
        {
            "time": "",
            "original_text": "扎堆上市 狂并购买连锁药店不缺资金缺管理",
            "features": {
                "keywords": [
                    "扎堆上市",
                    "并购",
                    "连锁药店",
                    "资金",
                    "管理"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "扎堆上市 狂并购买连锁药店不缺资金缺管理",
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "大参林今日大宗交易成交5.61万股，成交价42.21元折价9.21%",
            "features": {
                "keywords": [
                    "大参林",
                    "大宗交易",
                    "折价"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "大参林今日大宗交易成交5.61万股，成交价42.21元折价9.21%",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "大参林现1笔大宗交易 共成交236.80万元",
            "features": {
                "keywords": [
                    "大参林",
                    "大宗交易"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "大参林现1笔大宗交易 共成交236.80万元",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业：十三五开启血制品新成长周期 重点推荐天坛生物、博雅生物等",
            "features": {
                "keywords": [
                    "医药生物",
                    "十三五",
                    "血制品",
                    "成长周期",
                    "天坛生物",
                    "博雅生物"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业：十三五开启血制品新成长周期 重点推荐天坛生物、博雅生物等",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]